WO2007084441A3 - Novel fsh glycosylation variant d3n - Google Patents

Novel fsh glycosylation variant d3n Download PDF

Info

Publication number
WO2007084441A3
WO2007084441A3 PCT/US2007/001004 US2007001004W WO2007084441A3 WO 2007084441 A3 WO2007084441 A3 WO 2007084441A3 US 2007001004 W US2007001004 W US 2007001004W WO 2007084441 A3 WO2007084441 A3 WO 2007084441A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycosylation variant
novel
fsh glycosylation
novel fsh
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/001004
Other languages
French (fr)
Other versions
WO2007084441A2 (en
Inventor
Marco Muda
Xuliang Jiang
Sean D Mckenna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Serono Laboratories UK Ltd
Original Assignee
Laboratoires Serono SA
Serono Laboratories UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT07716617T priority Critical patent/ATE487738T1/en
Priority to EP07716617A priority patent/EP1981908B1/en
Priority to CN2007800030734A priority patent/CN101370825B/en
Priority to BRPI0706628-7A priority patent/BRPI0706628A2/en
Priority to US12/158,539 priority patent/US7956034B2/en
Priority to HR20100610T priority patent/HRP20100610T1/en
Priority to JP2008551305A priority patent/JP2009523445A/en
Priority to DK07716617.1T priority patent/DK1981908T3/en
Priority to DE602007010425T priority patent/DE602007010425D1/en
Priority to PL07716617T priority patent/PL1981908T3/en
Priority to AU2007207697A priority patent/AU2007207697B2/en
Priority to EA200870177A priority patent/EA013974B1/en
Application filed by Laboratoires Serono SA, Serono Laboratories UK Ltd filed Critical Laboratoires Serono SA
Priority to SI200730438T priority patent/SI1981908T1/en
Priority to CA002633844A priority patent/CA2633844A1/en
Publication of WO2007084441A2 publication Critical patent/WO2007084441A2/en
Publication of WO2007084441A3 publication Critical patent/WO2007084441A3/en
Priority to IL192547A priority patent/IL192547A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

FSH mutant with increased glycosylation and longer half-life is described. The use of this FSH mutant for inducing folliculogenesis in human patients is also described.
PCT/US2007/001004 2006-01-17 2007-01-16 Novel fsh glycosylation variant d3n Ceased WO2007084441A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EP07716617A EP1981908B1 (en) 2006-01-17 2007-01-16 Novel fsh glycosylation variant d3n
CN2007800030734A CN101370825B (en) 2006-01-17 2007-01-16 Novel FSH glycosylation variant D3N
BRPI0706628-7A BRPI0706628A2 (en) 2006-01-17 2007-01-16 fsh d3n glycosylation variant
US12/158,539 US7956034B2 (en) 2006-01-17 2007-01-16 FSH glycosylation variant D3N
HR20100610T HRP20100610T1 (en) 2006-01-17 2007-01-16 Novel fsh glycosylation variant d3n
JP2008551305A JP2009523445A (en) 2006-01-17 2007-01-16 Novel FSH glycosylation mutant D3N
DK07716617.1T DK1981908T3 (en) 2006-01-17 2007-01-16 New FSH glycosylation variant D3N
PL07716617T PL1981908T3 (en) 2006-01-17 2007-01-16 Novel fsh glycosylation variant d3n
DE602007010425T DE602007010425D1 (en) 2006-01-17 2007-01-16 NEW FSH GLYCOSILATION VERSION D3N
AT07716617T ATE487738T1 (en) 2006-01-17 2007-01-16 NEW FSH GLYCOSYLATION VARIANT D3N
EA200870177A EA013974B1 (en) 2006-01-17 2007-01-16 Mutant gen and use thereof
AU2007207697A AU2007207697B2 (en) 2006-01-17 2007-01-16 Novel FSH glycosylation variant D3N
SI200730438T SI1981908T1 (en) 2006-01-17 2007-01-16 Novel fsh glycosylation variant d3n
CA002633844A CA2633844A1 (en) 2006-01-17 2007-01-16 Novel fsh glycosylation variant d3n
IL192547A IL192547A (en) 2006-01-17 2008-06-30 Fsh mutants, their preparation and pharmaceutical compositions containing them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75948606P 2006-01-17 2006-01-17
US60/759,486 2006-01-17

Publications (2)

Publication Number Publication Date
WO2007084441A2 WO2007084441A2 (en) 2007-07-26
WO2007084441A3 true WO2007084441A3 (en) 2007-09-07

Family

ID=38163618

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/001004 Ceased WO2007084441A2 (en) 2006-01-17 2007-01-16 Novel fsh glycosylation variant d3n

Country Status (22)

Country Link
US (1) US7956034B2 (en)
EP (1) EP1981908B1 (en)
JP (1) JP2009523445A (en)
KR (1) KR20080094697A (en)
CN (1) CN101370825B (en)
AR (1) AR059054A1 (en)
AT (1) ATE487738T1 (en)
AU (1) AU2007207697B2 (en)
BR (1) BRPI0706628A2 (en)
CA (1) CA2633844A1 (en)
CY (1) CY1110953T1 (en)
DE (1) DE602007010425D1 (en)
DK (1) DK1981908T3 (en)
EA (1) EA013974B1 (en)
HR (1) HRP20100610T1 (en)
IL (1) IL192547A (en)
PL (1) PL1981908T3 (en)
PT (1) PT1981908E (en)
RS (1) RS51792B (en)
SI (1) SI1981908T1 (en)
WO (1) WO2007084441A2 (en)
ZA (1) ZA200805194B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG155183A1 (en) * 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
EP1960419B1 (en) 2005-12-09 2016-03-16 Ares Trading S.A. Method for purifying fsh or a fsh mutant
MX2008008322A (en) * 2005-12-22 2008-10-01 Serono Lab Fsh mutants.
CA2701221A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying an fc-containing protein
EP2203474A1 (en) * 2007-10-22 2010-07-07 Merck Serono S.A. Method for purifying fc-fusion proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058493A1 (en) * 2000-02-11 2001-08-16 Maxygen Aps Conjugates of follicle stimulating hormones
WO2004050679A2 (en) * 2001-10-22 2004-06-17 Applied Research Systems Ars Holding N.V. Mutant glycoproteins
WO2005020934A2 (en) * 2003-09-02 2005-03-10 Applied Research Systems Ars Holding N.V. Fsh glycosylation mutant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0996629T1 (en) * 1997-06-25 2006-12-31 Applied Research Systems Disulfide crosslinked glycoprotein hormone analogs, their preparation and use
EP1960419B1 (en) * 2005-12-09 2016-03-16 Ares Trading S.A. Method for purifying fsh or a fsh mutant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058493A1 (en) * 2000-02-11 2001-08-16 Maxygen Aps Conjugates of follicle stimulating hormones
WO2004050679A2 (en) * 2001-10-22 2004-06-17 Applied Research Systems Ars Holding N.V. Mutant glycoproteins
WO2005020934A2 (en) * 2003-09-02 2005-03-10 Applied Research Systems Ars Holding N.V. Fsh glycosylation mutant

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq [online] 29 January 2002 (2002-01-29), "Human FSH-alpha subunit mutant D3N/Q5S.", XP002439755, retrieved from EBI accession no. GSP:AAM51735 Database accession no. AAM51735 *
DATABASE Geneseq [online] 29 January 2002 (2002-01-29), "Human FSH-alpha subunit mutant D3N/Q5T.", XP002439754, retrieved from EBI accession no. GSP:AAM51736 Database accession no. AAM51736 *
FURUHASHI MADOKA ET AL: "Effect of additional N-glycosylation signal in the N-terminal region on intracellular function of the human gonadotropin alpha-subunit.", ENDOCRINE JOURNAL, vol. 50, no. 3, June 2003 (2003-06-01), pages 245 - 253, XP002439749, ISSN: 0918-8959 *
PERLMAN S ET AL: "Glycosylation of an N-terminal extension prolongs the half-life and increases the in-vivo activity of follicle stimulating hormone", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, ENDOCRINE SOCIETY, CHEVY CHASE, MD, US, vol. 88, no. 7, July 2003 (2003-07-01), pages 3227 - 3235, XP002390383, ISSN: 0021-972X *
WEENEN C ET AL: "Long-acting follicle-stimulating hormone analogs containing N-linked glycosylation exhibited increased bioactivity compared with O-linked analogs in female rats", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 89, no. 10, October 2004 (2004-10-01), pages 5204 - 5212, 5196, XP002439750, ISSN: 0021-972X *

Also Published As

Publication number Publication date
IL192547A (en) 2012-04-30
EP1981908B1 (en) 2010-11-10
HRP20100610T1 (en) 2010-12-31
EA200870177A1 (en) 2009-02-27
EP1981908A2 (en) 2008-10-22
WO2007084441A2 (en) 2007-07-26
AR059054A1 (en) 2008-03-12
CN101370825A (en) 2009-02-18
EA013974B1 (en) 2010-08-30
IL192547A0 (en) 2009-02-11
CA2633844A1 (en) 2007-07-26
US7956034B2 (en) 2011-06-07
AU2007207697A1 (en) 2007-07-26
ATE487738T1 (en) 2010-11-15
JP2009523445A (en) 2009-06-25
KR20080094697A (en) 2008-10-23
AU2007207697B2 (en) 2012-01-19
BRPI0706628A2 (en) 2011-04-05
PT1981908E (en) 2010-11-23
DK1981908T3 (en) 2010-12-13
US20080280832A1 (en) 2008-11-13
CY1110953T1 (en) 2015-06-11
ZA200805194B (en) 2009-10-28
PL1981908T3 (en) 2011-04-29
RS51792B (en) 2011-12-31
CN101370825B (en) 2012-10-10
DE602007010425D1 (en) 2010-12-23
SI1981908T1 (en) 2011-01-31
AU2007207697A2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
WO2003061593A3 (en) Novel targeted compositions for diagnostic and therapeutic use
CA104272S (en) Video monitor
MXPA05008406A (en) Phenylacetamides and their use as glucokinase modulators.
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
IL181234A0 (en) Mixture of phytosterol ester(s) and 1,3-diglycerides(s) for use in the treatment of medical conditions
EP1713547A4 (en) Patient interface assembly supported under the mandible
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
IL214198A0 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling
WO2006097535A3 (en) Peptide agonists of the glucagon family with secretin like activity
WO2007084441A3 (en) Novel fsh glycosylation variant d3n
WO2004031352A3 (en) Interferon variants with improved properties
CA115335S (en) Massage chair
SI2185561T1 (en) 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo(1,2-a)-diazepine-7-carboxamide derivatives, preparation and therapeutic use thereof
CA115333S (en) Massage chair
CA115340S (en) Massage chair
CA115337S (en) Massage chair
AU2002319296A1 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with CGMP regulated processes
WO2005020934A3 (en) Fsh glycosylation mutant
WO2008010840A3 (en) Fsh mutants
AU2003268484A1 (en) Delivery of therapeutics to the brain and spinal cord
WO2006020430A8 (en) Novel composition and methods for the treatment of immune related disease
AU2003293500A1 (en) Lactoferrin in the reduction of pain
AU2003214701A1 (en) Mattress with adjustable hardness
AU2003217432A1 (en) Angiopoietin-1 in the treatment of disease
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2633844

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12158539

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2007207697

Country of ref document: AU

Ref document number: 5438/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200780003073.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/009199

Country of ref document: MX

Ref document number: 2008551305

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2007207697

Country of ref document: AU

Date of ref document: 20070116

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007716617

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020087020053

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200870177

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: P-2010/0568

Country of ref document: RS

ENP Entry into the national phase

Ref document number: PI0706628

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080716